After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Early data with the RIPTAC HLD-0915 look competitive.
